European Panel Recommends Broader Use of Trelegy Ellipta for COPD Patients

The triple therapy inhaler Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) has received a positive recommendation from the European Medicines Agency (EMA)‘s Committee for Medicinal Products for Human Use (CHMP) to expand its use to a broader population of chronic obstructive pulmonary disease (COPD) patients.

FDA Advisory Committee Does Not Support Approval of GSK’s Mepolizumab for COPD

The U.S. Food & Drug Administration’s Pulmonary Allergy Drugs Advisory Committee voted that the risk-benefit profile of GSK’s mepolizumab was not adequate to support its approval as an add-on treatment for reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who are on maximum corticosteroid-based…